LEXX Lexaria Bioscience Corp
Price (delayed)
$1.67
Market cap
$29.31M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.5
Enterprise value
$21.37M
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's
Highlights
Lexaria Bioscience's equity has soared by 161% YoY and by 22% from the previous quarter
The gross profit has soared by 91% YoY and by 8% from the previous quarter
The EPS rose by 40% year-on-year but it has declined by 6% since the previous quarter
The net income has decreased by 26% QoQ and by 20% YoY
Key stats
What are the main financial stats of LEXX
Market
Valuations
Earnings
Shares outstanding
17.55M
Market cap
$29.31M
Enterprise value
$21.37M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.98
Price to sales (P/S)
56.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
43
Revenue
$496,923
Gross profit
$494,203
Operating income
-$7.3M
Net income
-$7.32M
EBIT
-$7.32M
EBITDA
-$7.2M
Free cash flow
-$6.57M
Per share
Balance sheet
Liquidity
EPS
-$0.5
EPS diluted
-$0.5
Free cash flow per share
-$0.39
Book value per share
$0.56
Revenue per share
$0.03
TBVPS
$0.56
Total assets
$9.79M
Total liabilities
$399,718
Debt
$130,732
Equity
$9.77M
Working capital
$8.53M
Debt to equity
0.01
Current ratio
29.64
Quick ratio
28.36
Net debt/EBITDA
1.1
Margins
Efficiency
Dividend
EBITDA margin
-1,449.2%
Gross margin
99.5%
Net margin
-1,473%
Operating margin
-1,470%
Return on assets
-83.6%
Return on equity
-85%
Return on invested capital
-701.5%
Return on capital employed
-77.1%
Return on sales
-1,473%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LEXX stock price
How has the Lexaria Bioscience stock price performed over time
Intraday
1.83%
1 week
-7.07%
1 month
13.61%
1 year
-51.87%
YTD
-20.48%
QTD
-2.34%
Financial performance
How have Lexaria Bioscience's revenue and profit performed over time
Revenue
$496,923
Gross profit
$494,203
Operating income
-$7.3M
Net income
-$7.32M
Gross margin
99.5%
Net margin
-1,473%
The gross profit has soared by 91% YoY and by 8% from the previous quarter
LEXX's revenue has surged by 78% year-on-year and by 7% since the previous quarter
The net margin rose by 32% year-on-year but it has declined by 18% since the previous quarter
The operating margin is up by 31% year-on-year but it has declined by 19% since the previous quarter
Growth
What is Lexaria Bioscience's growth rate over time
Valuation
What is Lexaria Bioscience stock price valuation
P/E
N/A
P/B
2.98
P/S
56.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
43
The EPS rose by 40% year-on-year but it has declined by 6% since the previous quarter
Lexaria Bioscience's equity has soared by 161% YoY and by 22% from the previous quarter
LEXX's P/B is 47% below its last 4 quarters average of 5.5 and 32% below its 5-year quarterly average of 4.3
LEXX's revenue has surged by 78% year-on-year and by 7% since the previous quarter
The stock's price to sales (P/S) is 45% less than its last 4 quarters average of 99.2 and 17% less than its 5-year quarterly average of 66.1
Efficiency
How efficient is Lexaria Bioscience business performance
Lexaria Bioscience's ROE has increased by 44% YoY but it has decreased by 4.2% from the previous quarter
Lexaria Bioscience's ROA has increased by 42% YoY but it has decreased by 4.1% from the previous quarter
The return on sales rose by 32% year-on-year but it has declined by 18% since the previous quarter
The company's return on invested capital fell by 31% QoQ and by 12% YoY
Dividends
What is LEXX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LEXX.
Financial health
How did Lexaria Bioscience financials performed over time
The total assets has soared by 170% YoY and by 10% from the previous quarter
The total liabilities has dropped by 67% since the previous quarter but it has surged by 57% year-on-year
The debt is 99% smaller than the equity
Lexaria Bioscience's equity has soared by 161% YoY and by 22% from the previous quarter
LEXX's debt to equity has shrunk by 75% YoY and by 50% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.